D
URING THE LAST years, high-density microarray technology has become a powerful tool used to analyze gene expression profiles, namely to identify genes and groups of genes that are characterized by a differential mRNA expression pattern in various experimental conditions. It has been used to analyze both benign and malignant thyroid pathologies, i.e. autonomously functioning thyroid nodules (AFTNs), cold thyroid nodules (CTNs), papillary thyroid carcinomas (PTCs), and follicular thyroid carcinomas (FTCs) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) in 12 studies using Affymetrix GeneChips (1-6, 9 -13, 16) . The important differences between these studies involved the use of different generations of GeneChips and intraindividual vs. interindividual comparisons. Moreover, the definition of the reference tissue varied between the studies; although it meant strictly nonnodular healthy tissue in some studies (1, 5, 9, 10, 15) , it also comprised follicular adenoma and hyperplastic nodules in other studies (6, 11, 12, 16) . The variability of reference tissues might be of minor importance in studies looking for diagnostic markers of malignant tumors such as follicular and PTC. However, in studies whose main objective is to identify the etiology of a specific thyroid pathology and to define signaling cascades that are involved or affected in this pathology, the nature/origin of the reference tissue is likely to be crucial.
Recently, we investigated mRNA expression profiles of AFTNs (5) and CTNs (9) , each in comparison with their normal surrounding tissue (ST), using the Affymetrix GeneChip U95Av2. In these studies, we focused on the identification of gene sets (e.g. signaling cascades) that differentiate between nodular tissue and normal ST and identified an inactivation of the TGF-␤ signaling cascade in AFTNs (5) and an increased expression of cell cycle-associated genes in CTNs (9) . In another study, Jarzab et al. (10) analyzed the gene expression profiles of PTCs in comparison with benign/ normal tissue obtained from either the same patients (intraindividual comparisons) or from other individuals (interindividual comparisons) using Affymetrix U133A GeneChips, with the goal of generating a diagnostic multigene classifier distinguishing between the PTCs and benign/normal tissues.
Because of the increasing number of oligonucleotide chip analyses of different thyroid pathologies, the question of data comparability is emerging. In this study, we therefore combined our data sets of AFTNs, CTNs, PTCs, and normal STs. This approach served both to identify biologically significant pathways in PTC and to confirm the specificity of the multigene PTC classifier and required the investigation of the comparability of different GeneChip generations as well as the evaluation of the influence of intra-and interindividual comparisons on gene expression profiling results. Moreover, we used our previously described algorithms to propose two support vector machine (SVM)-based classifiers for AFTNs and CTNs as the first application of this method to benign thyroid diseases, and we performed cross-comparisons to validate their efficacy.
Patients and Methods
The GeneChip methods assays were performed according to the manufacturer's instructions and described in detail previously (5, 9, 10) . Although 15 AFTNs and 22 CTNs were obtained as paired tissue samples from the same patients (AFTN-P-U95 and CTN-P-U95, respectively), the tissues from the PTC study were subdivided into two subsets: an initial group consisting of 16 PTCs, which were obtained also as paired tissue samples from the same patients (PTC-P-U133), and a validation group consisting of seven additional PTCs and 11 normal/ benign thyroid samples (PTC-U-U133). AFTNs, CTNs, and their ST samples were hybridized to U95Av2 GeneChips, whereas U133A GeneChips were used in the PTC study. In addition, U95A GeneChip data for eight PTCs and their normal STs analyzed by Huang et 
Data analysis
Data preprocessing. Affymetrix GeneChip data were scaled to normalize data for interarray comparison using Affymetrix MAS 5.0 software.
To compare the expression data of AFTNs and CTNs (GeneChip U95A, 12,625 probe sets) with the PTCs expression data (GeneChip U133A, 22,283 probe sets), we used Affymetrix Best Match Comparison Spreadsheet Human Genome U95 to Human Genome U133, which yielded an intersection of 10,507 probe sets (www.affymetrix.com/ support/technical/comparison_spreadsheets.affx).
Principal component analysis (PCA).
First, the expression data matrix of 10,507 probe sets from the 140 GeneChips was subjected to PCA to view the overall trend of the data set. PCA allows the identification of key variables in a multidimensional data set, which explain the differences between the experiments in the best way. When assuming m experiments, each with n genes, the aim of the PCA is to reduce the dimensionality of the data matrix by the identification of r Յ n new variables. These r principal components explain the variance of the original n variables as well as possible, while they are uncorrelated and orthogonal. This reduction of dimensionality allows an improved data visualization and analysis.
To detect differentially regulated genes and gene sets, different methods of data analysis were used.
Empirical filtering. We selected genes that had a signal log ratio greater than 0.585 or lower than Ϫ0.585 in at least 85% of the comparisons (i.e. these genes are characterized by a minimum 1.5-fold change).
Application of the Westfall-Young strategy to genes. To avoid a high rate of false positive results in this multitude of tests for the different genes, we added so-called multiple test procedures. After a logarithmic transformation of the data, we computed adjusted P values for each gene according to the Westfall-Young procedure, which imbeds univariate F tests into a permutation procedure (17) . This procedure keeps the familywise error rate ␣ in the strong sense, i.e. the lot of all selected genes may contain a false positive gene with the probability ␣, at most.
GenMAPP. In contrast to statistical filters and pattern-finding algorithms (e.g. hierarchical clustering), GenMAPP (Gene Microarray Pathway Profiler, www.GenMAPP.org) analyzes the gene expression changes in the context of known biological pathways (18) . Gene expression data, including P values, were imported into GenMAPP in a comma-separated value file format. GenMAPP converts the expression data into a data set that can then be viewed on any microarray pathway profile with any number of color-coding criteria set. The following color-coding criteria were defined. Significantly (P Ͻ 0.05) up-regulated genes are colored red and significantly down-regulated genes are colored green.
Recursive feature replacement (RFR). RFR (19, 20) is an iterative method based on the SVM technique (21) with the goal of finding an optimal gene subset in a leave-one-out cross-validation approach. In an iterative manner, it looks for gene sets, not for single genes, to evaluate their classification quality and to select the best one. RFR is similar to the standard recursive feature elimination algorithm (22) and uses recursive feature elimination to find starting gene sets. Recently, a superior quality of classification compared with RFR has been shown (10) .
Results

Comparison of expression data derived from different GeneChip generations
First, we investigated the influence of the GeneChip generation on the expression patterns of different thyroid tissue entities. For this purpose, we compared the mRNA expression profiles of AFTNs, CTNs, and PTCs hybridized to two generations of Affymetrix GeneChips (AFTNs and CTNs, U95Av2; PTCs, U95A/U133A). The expression data matrix derived from 140 microarrays altogether was subjected to PCA to analyze the overall trend within the data set. Much stronger differences between the expression patterns of PTC samples hybridized to different GeneChip generations than between the expression patterns of the different tissue entities were observed ( Fig. 1 ). Therefore, a direct combination of data obtained by different GeneChip generations is not possible.
Comparison of paired and unpaired data sets
Three different PTC data sets were used for this comparison: two data sets of paired samples, Huang's data set comprising eight PTCs with their normal STs hybridized to GeneChips U95A (PTC-P-U95) (1) and Jarzab's initial data set comprising 16 PTCs and their STs hybridized to GeneChips U133A (PTC-P-U133) (10) , and one unpaired data set, Jarzab's validation set comprising seven PTCs and 11 unpaired benign samples, also hybridized to GeneChips U133A (PTC-U-U133) (10) . Each data set was independently analyzed using our empirical filters and the statistical analysis of individual probe sets according to Westfall-Young. Subsequently, the results of these two algorithms in the three different data sets were compared (Fig. 2) . Using the filter algorithm, we found 60 up-regulated probe sets in the PTC-P-U95 data set with an overlap of 39 probe sets to the PTC-P-U133 data set, which comprised 115 up-regulated probe sets. The analysis of the PTC-U-U133 data set according to the filter algorithm revealed 121 up-regulated probe sets, but only one gene (glutaminyl cyclase) was also found in the other two data sets. Similar results were observed in the group of down-regulated genes (Fig. 2) . Sixteen downregulated probe sets were found in the PTC-P-U95 data set with an overlap of five probe sets (two probe sets representing trefoil factor 3 intestinal, two probe sets representing dermatopontin, and one cellular retinoic acid binding protein 1) with the PTC-P-U133 data set, which comprised 79 down-regulated probe sets, whereas we found 52 downregulated probe sets in the PTC-U-U133 data set without any overlap to the two paired data sets.
The comparison of the Westfall-Young analysis results revealed a similar lack of overlap (Fig. 2) . In the PTC-P-U95 data set, we found only three significant probe sets (odz odd Oz/ten-m Drosophila homolog 1, dual specificity phosphatase 6, syndecan 4) but all of them belonged also to the group of 549 significant probe sets from the PTC-P-U133 data set. In the unpaired PTC-U-U133 data set, we found 14 significant probe sets with an overlap of four probe sets (3-phos- (1), which were all hybridized to Affymetrix GeneChips U95A(v2), and of the expression data of the 23 PTCs and 27 surrounding/normal tissues (10), which were hybridized to Affymetrix GeneChips U133A. This analysis reveals higher differences between the different GeneChip generations than between the different entities of thyroid tissues.
FIG. 2.
Comparison of the differentially expressed genes between the PTC-P-U95 data set of paired samples of PTCs and STs (1), the PTC-P-U133 data set of paired samples of PTCs and STs (10) , and the PTC-U-U133 data set of PTCs and unpaired benign thyroid tissues (10) identified by empirical filters and Westfall-Young analysis. Although different GeneChip generations were used in the two studies, there is a higher overlap between the differentially expressed genes of the paired data sets (PTC-P-U95 and PTC-P-U133) than the PTC-P-U133 data set and the PTC-U-U133 data set, which were analyzed with the same GeneChip generation.
phoadenosine-5-phosphosulfate synthase 1, tumor suppressing subtransferable candidate 3, keratin 19, copine III) to the PTC-P-U133 data set.
GenMAPP analysis of PTCs
GenMAPP software was used to visualize and analyze the GeneChip data on microarray pathway profiles. The significant changes within the MAPK signaling pathway could be identified when the PTC-P-U95 and the PTC-P-U133 data sets were analyzed (Fig. 3) . In both cases, we found a significantly increased expression of H-RAS, R-RAS, microtubule-associated protein 2, and RAS GTPase-activating protein 1 and a significantly decreased expression of the protooncogene c-fos in the PTCs in comparison with their normal STs. Moreover, we found a significant up-regulation of MEK kinase 1, MAP kinase kinase 1, MAP kinase 1, and the tyrosine kinase Elk-1 in the PTC-P-U133 data set. Furthermore, this data set is characterized by a significantly down-regulated expression of N-RAS and an additional probe set representing the MAP kinase kinase 1 in the PTCs. GenMAPP analysis did not point out the significance of MAPK signaling pathway when applied to the unpaired PTC data set (PTC-U-U133).
Classification of benign thyroid nodules by RFR-based multigene classifier of PTCs
The aim of this step was to verify the molecular classifier differentiating PTC and normal thyroid tissue, which consists of 20 genes selected by the RFR technique (19, 20) proposed recently (10) . We intended to validate its specificity on a large collection of benign thyroid tissues: AFTNs, CTNs, and their normal STs. After normalization, the probe sets of the AFTN-P-U95 and the CTN-P-U95 data set were matched to the probe sets proposed by the RFR-20 molecular classifier (10) , and a classification of all data sets was performed (Fig.  4) . Also, at the conditions used in this study, our approach correctly classified all PTCs and STs from the PTC-P-U95 data set. Moreover, all benign tissues (AFTNs, CTNs, and their normal STs) were classified as normal/benign and have been assigned with very similar classification function values as the normal STs of the PTC-P-U95 data set.
SVM-based classifiers for benign thyroid nodules
Multigene classifiers for AFTNs and CTNs were specified by the RFR algorithm. The procedures used in SVM analysis were the same as those used to build the PTC classifier (10), and two classifiers consisting of 20 genes were derived. Both classifiers were compared for their ability to classify other thyroid tissues, first within the same GeneChip generation (AFTN classifier on CTN-P-U95 data set, CTN classifier on AFTN-P-U95 data set, both on PTC-P-U95), then with U133A chips on the combined data set, including our 23 PTCs and 51 PTCs as made available by Giordano et al. (2) (PTC-U133 data set). The genes included into the AFTN classifier are shown in Table 1 , and the cross-classification result is shown in Fig. 5 The genes included in the CTN classifier are shown in Table 2 , and the cross-classification result is shown in Fig. 5 , E-H. In contrast to the AFTN classifier, all PTCs from the PTC-P-U95 data set and the majority from U133 sets (F and G) were recognized as CTNs (only one was clearly defined as non-CTN, Fig. 5F ). Only two from all normal/benign thyroid tissues were classified as CTNs. From the AFTNs analyzed, nine (60%) exhibited molecular features of a CTN, whereas only two were definitely diagnosed as non-CTNs.
Discussion
High-density oligonucleotide microarray studies enable cross-validation of their results by comparison of data obtained in different centers, provided the appropriateness of the methods of comparison. For this purpose, we combined our paired and unpaired GeneChip data sets of AFTNs, CTNs, and PTCs as well as the publicly available PTC data sets (1, 2) and attempted to evaluate the following issues: the feasibility of comparing GeneChip data obtained using different GeneChip generations (5, 9, 10), the reanalysis of expression data in the biological as well as diagnostic context and, eventually, the feasibility of building multigene classifiers for benign tissues.
Comparison of expression data derived from different GeneChip generations
Before comparing the mRNA expression patterns of AFTNs, CTNs, and PTCs, which were hybridized to different generations of GeneChips, we asked how differences in oligo DNA and chip design influence the expression patterns of the different entities of thyroid tissues. Despite the use of the Affymetrix Best Match Comparison Spreadsheet, we observed much stronger differences between the expression patterns of the PTC samples hybridized to different GeneChip generations than between the expression patterns of the different tissue entities. These differences of the signal intensities most likely   FIG. 4 . Classification of samples based on RFR20 molecular classifier to distinguish between PTCs and normal thyroid (10) . A, PTC-P-U133 data set of 16 PTC and 16 normal thyroid tissues (10) . B, PTC-U-U133 data set from the same paper. C, PTC-P-U95 data set of eight PTC and eight normal thyroid samples (1). D, Data for 15 AFTNs and 22 CTNs (AFTN-P-U95 and CTN-P-U95) (5, 9) . Positive values denote diagnosis of PTC, and negative values denote diagnosis of normal thyroid. The shaded box is the arbitrarily marked area where the classifier does not respond (not assessed). In addition to the Affymetrix probe set identification, gene title and gene symbol are given.
are attributed to the degree of dissimilarity of probe sets, expression level of the corresponding transcript (23, 24) , and technical differences such as different scanner settings. Therefore, to be able to compare our previous results (5, 9, 10) with the present re-and meta-analysis, different entities were analyzed separately. Only afterward were the results compared between the different thyroid pathologies.
Comparison of paired and unpaired data sets
In some reports, intraindividual comparisons of diseased tissue with normal (surrounding) tissue were performed, whereas in other reports, pathologic and normal tissues from different individuals were compared. To address the relevance of paired (intraindividual) vs. unpaired data sets, we
FIG. 5. Upper panel, Molecular classifier to distinguish between AFTNs and normal thyroid tissue, applied to other thyroid tissues. A, CTNs and corresponding normal tissues (CTN-P-U95). B, PTCs and normal tissues (PTC-P-U133 and PTC-U-U133) (10). C, PTCs and normal tissues (U133) (16). D, PTCs and corresponding normal tissue (PTC-P-U95) (1).
Lower panel, Molecular classifier to distinguish between CTNs and normal thyroid tissue, applied to other thyroid tissues. E, AFTNs and corresponding normal tissues (AFTN-P-U95). F, PTCs and normal tissues (PTC-P-U133 and PTC-U-U133) (10). G, PTC and normal tissues (U133) (16) . H, PTCs and corresponding normal tissue (PTC-P-U95) (1). Chemokine (C-X-C motif) ligand 12 CXCL12 483_g_at
Cadherin 13  CDH13  33966_at  IL-7  IL7  31523_f_at  Histone 1, H2be  HIST1H2BE  1451_s_at  Periostin  POSTN  40511_at  GATA binding protein 3  GATA3  39593_at  Similar to fibrinogen-like 2  36939_at  Glycoprotein M6A  GPM6A  206_at  Cathepsin E  CTSE  286_at  Histone 2, H2aa  HIST2H2AA  36852_at  Tumor suppressor candidate 3  TUSC3  31731_at  Chromobox homolog 4  CBX4  36892_at Integrin, ␣ 7 ITGA7
In addition to the Affymetrix probe set identification, gene title and gene symbol are given.
Eszlinger et al.
• 1934 -1942 1939 compared the results of empirical filters and Westfall-Young analysis among the PTC-P-U133 (10), PTC-P-U95 (1), and PTC-U-U133 (10) data sets (Fig. 2) . The results of these comparisons clearly indicate the quality of paired data sets; despite the different GeneChip generations that were used in the PTC-P-U133 and PTC-P-U95 data sets, these two paired data sets share more similarities in gene expression profiles than the two U133A data sets (PTC-P-U133 and PTC-U-U133), which were generated in the same laboratory under identical conditions and scanned on the same GeneChip scanner. Especially in studies whose objective is the identification of subtle differences to elucidate the etiology of a specific pathology or to identify signaling cascades that are affected in this pathology, the definition of the reference tissue seems to be a crucial step for the analysis of the gene expression profiles. This conclusion is further supported by the results of the GenMAPP analysis of the PTC samples.
Although both paired data sets show a significantly changed expression pattern of the MAPK cascade in the PTCs (Fig. 3) , the unpaired data set provides no indications for this alteration (data not shown).
Reanalysis of PTCs for GenMAPP
In PTCs, several mutations and chromosomal rearrangements of genes coding for effectors along the MAPK pathway have been shown to be essential for the transformation of thyroid epithelial cells (25) . In about 70% of all PTCs, activating mutations or chromosomal rearrangements of BRAF, RET, or RAS have been identified (8, 26 -28) . Interestingly, even in the study by Giordano et al. (2) , who specified gene expression signatures of PTC initiating mutations, a differential expression of MAPK cascade-associated genes was not very distinct (1, 6 -8, 10 -12, 14, 15) . Notwithstanding their interpretation that related RET/PTC induced cancers to the activation of PI3K pathway, it should be mentioned that the signal transduction of the MAPK cascade occurs mainly by posttranslational modifications (e.g. phosphorylation) and might be poorly visible on the level of mRNA. However, in contrast to the data of Huang et al. (1) and Jarzab et al. (10) , who did not find any of the MAPK cascade-associated genes to be differentially regulated, our GenMAPP analysis revealed a significantly increased expression pattern of various genes of the MAPK cascade (Fig. 3) . Furthermore, the Westfall-Young analysis applied to these gene sets (9) also revealed a significantly changed MAPK cascade signaling in the PTC-P-U133 data set (P ϭ 0.0016).
Verification of the SVM-based multigene classifier of PTCs on a large collection of benign thyroid tissues
We reassessed the specificity of the previously published molecular classifier consisting of 20 genes selected by RFR in the PTC-P-U133 data set (10) using a far larger collection of benign thyroid tumors analyzed by the U95 platform. Despite the matching performed, which diminished the number of evaluable genes, our gene set again correctly classified all PTCs from the PTC-P-U95 data set and all but two from the PTC-U-U133A data set. The remaining two misclassified samples gave values of the classifying function close to zero, and we therefore introduced the region for which samples could not be assessed (see Fig. 4 ). All of the benign tissues from the U95 platform were assigned the proper classification function values and diagnosed as benign.
SVM-based classifiers for benign thyroid nodules
Twenty gene-classifiers for AFTNs and CTNs were specified from the respective U95 data sets. During their creation, the leave-one-out cross-validation was applied. This method allows for validation of the obtained gene sets even if independent validation sets are unavailable (2) . An additional level of evaluation could be obtained by applying the AFTN classifier to the CTN and PTC data sets and for the CTN classifier by applying it to the AFTN and PTC data sets.
The AFTN classifier was specific for benign tissues analyzed, including benign/normal thyroid tissues from Jarzab's PTC data set as well as from the other published data sets (1, 2). The AFTN signature was not found in any of the PTCs analyzed, and we relate this finding to the low risk of malignancy in AFTNs. However, the AFTN classifier recognized also a subset of samples within CTNs. This should not be regarded as a failure of the SVM-based analysis. The classifier was built based on the differences between AFTNs and normal thyroid tissue, both of which demonstrate iodine uptake and thyroid hormone secretion. Therefore, the list of genes included in the AFTN classifier (Table 1) was built from genes participating in other processes, some of which might be commonly affected in all benign tumors. In the selected gene set, cell adhesion and extracellular matrixrelated genes (SDC2, COL9A3, TNC, and NID) were found, genes belonging to the wide group of growth process/apoptosis/immune response, two metallothioneins, which also participate in proliferation/apoptosis and immune processes, and genes involved in signaling. One gene was transport-related (ABCA8), and four were attributed to metabolism regulation. Decreased expression of APOD and SDC2 as well as up-regulation of MT1F, SIAT1, and COL9A3 were indicated in our previous study (5) . Increased expression of MT1F and COL9A3 was also reported in benign tumors by Finley et al. (11) . Moreover, some of these genes may also be changed in thyroid cancer. APOD was indicated as a significantly down-regulated gene in oncocytomas and in FTC by Baris et al. (29) and Aldred et al. (3) , respectively, and tenascin C was found to be overexpressed in thyroid carcinomas by Finley et al. (11) .
Considering the CTN classifier, in agreement with our previous study showing the involvement of cell cycle genes in the gene expression profile of CTNs (9), mainly genes related to proliferation and growth processes were included (Table 2) . By previous approaches performed on the same data set, we found an overexpression of histone H2A family O and L members, and the first of them was included in the CTN classifier in the present study, together with a gene of the same family (histone H2BE). Another gene previously selected by us is GPM6A, a plasma membrane protein, downregulated in CTNs. The CTN classifier also contains some genes considered by others as cancer specific; among them, FGFR1 found by Chevillard et al. (14) as down-regulated in follicular variant of PTC in comparison with the classic vari-ant, TLE4, found by Aldred et al. (3) as down-regulated in FTC, TUSC3 (N33) overexpressed in PTC (1) . GATA 3 (involved in immune response) is decreased in CTNs, whereas it is up-regulated in papillary vs. oncocytic thyroid cancer (29) .
Contrary to AFTN, the CTN multigene signature was found in PTCs (Fig. 5) . The reason why the CTN classifier positively scored PTCs could be the partly dedifferentiatiated and proliferating phenotype of both entities. Moreover, the signature is recognizable even in some (one of three) AFTNs. Like CTNs (30, 31) , but less prominently, they also show increased proliferation.
We did not verify the single genes included in both classifiers because the SVM-based methods do not select single genes. They look for gene sets with the criterion of their best global classification ability and may include genes with minor change in expression pattern that provide complementary information and increase the classification quality of the whole gene set. It would be reasonable to validate both classifiers on independently collected hot thyroid nodules and CTNs; however, such data sets are not yet available.
In conclusion, although the recent studies show a high reproducibility even across microarray platforms by other approaches (32, 33) , for thyroid tissues we could show that a comparison of gene expression data generated on different GeneChip generations, which were preprocessed by Affymetrix MAS5.0 software, reveals a high reproducibility only when gene sets are selected within one study. Furthermore, our results point out another critical point for metaanalysis: the quality of the reference samples. A precise selection of intraindividual reference samples is mandatory to identify subtle changes in the expression patterns of signaling cascades, as we have shown in the case of the MAPK cascade in the PTCs. Moreover, we verify the SVMbased PTC classifier, published previously, as highly specific and propose similar multigene classifiers for AFTNs and CTNs.
